Printer Friendly

ADC Therapeutics Expands to Third Programme Using Synaffix's ADC Platform Under Existing Agreement.

M2 PHARMA-May 30, 2019-ADC Therapeutics Expands to Third Programme Using Synaffix's ADC Platform Under Existing Agreement

(C)2019 M2 COMMUNICATIONS

- Swiss oncology drug discovery and development company ADC Therapeutics has triggered a third target-specific license under an existing Commercial License Agreement dated October 2016 with Dutch biotechnology company Synaffix B.V., Synaffix said.

This license provides ADC Therapeutics with the rights to Synaffix's proprietary GlycoConnect site-specific antibody-drug conjugation and HydraSpace polar spacer technologies to develop and commercialize a third product candidate against a specific target.

Under the terms of the agreement, Synaffix is eligible to receive upfront, milestone and royalty payments on a per-target basis. Further financial details were not disclosed.

The clinical-stage GlycoConnect and HydraSpace technologies enable best-in-class ADCs with significantly enhanced efficacy and tolerability. GlycoConnect is the conjugation technology that exploits the native glycan for site-specific and stable payload attachment. HydraSpace is the compact and highly polar spacer technology.

These technologies can be applied directly to any existing antibody without any protein engineering and are compatible with all ADC payload classes.

The growing experience of Synaffix and its collaboration partners continues to confirm the ability of GlycoConnect and HydraSpace to consistently generate ADCs that are more effective and better tolerated when compared to the three major clinical-stage ADC conjugation technologies.

Synaffix B.V. is a Dutch biotechnology company that enables highly competitive ADC product candidates using its clinical-stage, site-specific ADC technology platform.

In addition to GlycoConnect and the ADC-enhancing HydraSpace technology, the extension of the platform with toxSYN payloads provides a fully complimentary technology platform that enables any company with an antibody to develop superior, proprietary ADC products.

The Synaffix platform comes with an IND-ready CMC package to support a rapid timeline to the clinic. Granted patents covering Synaffix's technology provide end-to-end protection of the platform technology as well as resulting products through at least 2035.

The business model of Synaffix is target-specific technology out-licensing as exemplified through its existing deals with Shanghai Miracogen, Mersana Therapeutics and ADC Therapeutics.

Synaffix is backed by a European, life science-focused investor syndicate that includes Aravis, BioGeneration Ventures, BOM Capital and M Ventures.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 30, 2019
Words:362
Previous Article:FDA Approves Revlimid In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone...
Next Article:X-Biotix Therapeutics Names DeJonge as Executive.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |